Få tillgång till
till ratingen av Finrange-aktier
till ratingen av Finrange-aktier
Med denna tariff kommer du att kunna använda tjänsten utan begränsningar, all information kommer att vara tillgänglig
Betyg Finrange
Uppkommande händelser Coeptis Therapeutics Holdings Inc
Alla evenemang
Inga kommande evenemang planerade
Sammanfattande analys Coeptis Therapeutics Holdings Inc
Få tillgång till
till ratingen av Finrange-aktier
till ratingen av Finrange-aktier
Med denna tariff kommer du att kunna använda tjänsten utan begränsningar, all information kommer att vara tillgänglig
Intäkter och nettointäkter Coeptis Therapeutics Holdings Inc
Alla parametrar
Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics Holdings, Inc. is headquartered in Wexford, Pennsylvania.
Adress:
105 Bradford Road, Wexford, PA, United States, 15090
